课题基金 / 基金详情

EXTENDING INDEPENDENCE AND QUALITY OF LIFE FOR PEOPLE WITH ALZHEIMER'S DISEASE OR DEMENTIA THROUGH TELEHEALTH PROGRAM DELIVERY

EXTENDING INDEPENDENCE AND QUALITY OF LIFE FOR PEOPLE WITH ALZHEIMER'S DISEASE OR DEMENTIA THROUGH TELEHEALTH PROGRAM DELIVERY
通过远程医疗计划的实施,提高阿尔茨海默病或痴呆症患者的独立性和生活质量
批准号:
10204865
负责人:
Deborah E. Barnes
金额:
$100.34万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2023-06-30

项目摘要

项目成果

Deborah E. Barnes的其他基金

相似基金

相关文献

中文摘要
翻译
使命声明:Together High Health,Inc.(Together)致力于帮助患有 阿尔茨海默病和相关疾病(ADRD)及其照顾者通过提供 在他们家里向他们直播基于证据的虚拟团体节目。意义:有以下几点 目前,美国有580万ADRD患者和1600多万无偿照顾者。当前 ADRD药物有助于缓解某些症状,但不会改变病程,通常会被停用 由于副作用。此外,大多数基于证据的行为干预--例如我们的面对面搬家 共同计划-在当地社区的人们并不广泛使用。创新:携手共进 通过使用以人为中心的设计原则来弥合这一差距-在该原则中,用户参与 设计和测试-开发和测试一个创新的、用户友好的平台,用于提供虚拟直播 为患有ADRD的人和家中的照顾者提供团体计划。调查人员:Together的首席执行官和 此应用程序的PI在以人为中心的设计方面拥有专业知识,并成功领导了我们的第一阶段小型企业 创新研究(SBIR)补助金。合作研究人员和顾问带来临床试验方面的专业知识,综合 健康、行为心理学、老年病学、定性方法、技术和教育。方法:第一阶段 进步。我们的第一阶段SBIR使我们能够为我们的独特方法开发和演示概念验证 直播虚拟团体节目的交付。我们已经完成或超过了我们所有的里程碑, 包括:1)与我们面对面项目的毕业生合作创建平台;2)试点-测试 平台在一群天真的用户中,以及3)完善平台,为第二阶段做准备。 是特别的,参与者强调了许多身体上、社交上、情感上和后勤上的好处。阶段 II目标:SBIR第二阶段拨款的主要目标是:1)确定直播虚拟群组 共同行动计划的实施改善了轻度ADRD患者和照顾者的生活质量, 包括探索潜在的作用机制;2)完善轻度认知障碍人群的平台 损害以扩大我们的目标受众;以及3)制定教师培训计划,以满足以下需求 更大的客户群。环境:Together的公司办公室位于旧金山,那里提供了丰富的 开发和测试以创新技术为基础的解决方案以解决具有挑战性的社会问题的环境 加州大学旧金山分校(UCSF)和旧金山分校的调查人员的参与加强了这一点 弗吉尼亚州弗朗西斯科。商业化计划:第二阶段完成后,我们将准备商业化 Together的远程医疗平台,最初使用的是客户付费模式,有明确的增长和扩张计划。 摘要:Together在直播虚拟群组基于证据的交付方面的创新方法 为患有ADRD的人和家中的照顾者提供的方案提供了巨大的潜力,以增加获得 并改善这一脆弱和服务不足人口的生活质量。
英文摘要
Mission Statement: Together Senior Health, Inc. (TOGETHER), is committed to helping people living with Alzheimer’s Disease and Related Disorders (ADRD) and their caregivers maximize quality of life by delivering livestreaming, evidence-based, virtual group programs to them in their homes. Significance: There are currently 5.8 million people in the U.S. living with ADRD and more than 16 million unpaid caregivers. Current ADRD medications help with some symptoms but do not change the disease course and are often stopped due to side effects. In addition, most evidence-based behavioral interventions—such as our in-person Moving Together program—are not widely available to people in their local communities. Innovation: TOGETHER is bridging this gap by using human centered design principles—in which the user is involved with all phases of design and testing—to develop and test an innovative, user-friendly platform for delivering livestreaming virtual group programs to people with ADRD and caregivers in their homes. Investigators: TOGETHER’s CEO and PI of this application has expertise in human centered design and successfully led our Phase I Small Business Innovation Research (SBIR) grant. Coinvestigators and consultants bring expertise in clinical trials, integrative health, behavioral psychology, geriatrics, qualitative methods, technology and education. Approach: Phase I Progress. Our Phase I SBIR enabled us to develop and demonstrate proof-of-concept for our unique approach to livestreaming virtual group program delivery. We have completed or exceeded all of our milestones, which included: 1) creating the platform in partnership with graduates of our in-person program; 2) pilot-testing the platform in a naïve group of users and 3) refining the platform in preparation for Phase II. The response has been exceptional, with participants highlighting many physical, social, emotional, and logistical benefits. Phase II Aims: The primary goals of this SBIR Phase II grant are to: 1) determine whether livestreaming virtual group delivery of the Moving Together program improves quality of life in people with mild ADRD and caregivers, including exploration of potential mechanisms of action; 2) refine the platform for people with mild cognitive impairment to expand our target audience; and 3) develop an instructor training program to meet the needs of a larger client base. Environment: TOGETHER’S corporate office is in San Francisco, which offers a rich environment for developing and testing innovative technology-based solutions to challenging social problems and is enhanced by involvement of investigators at the University of California, San Francisco (UCSF) and San Francisco VA. Commercialization Plan: After completion of Phase II, we will be prepared to commercialize TOGETHER’s telehealth platform, initially using a client pay model, with clear plans for growth and expansion. Summary: TOGETHER’s innovative approach to livestreaming virtual group delivery of evidence-based programs for people with ADRD and caregivers in their homes offers tremendous potential to increase access and improve quality of life in this vulnerable and under-served population.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1177/27536130231202989
发表时间: 2023-01
期刊: Global advances in integrative medicine and health
影响因子: --
作者: [Nicosia, Francesca M., Lee, Jennifer A., Chesney, Margaret A., Benjamin, Cynthia, Lee, Amanda N., Mehling, Wolf, Sudore, Rebecca L., Barnes, Deborah E.]
通讯作者: Barnes, Deborah E.
A Novel Algorithm to Identify People with Undiagnosed Alzheimer's Disease and Related Dementias
  • 批准号:
    10696912
  • 项目类别:
  • 资助金额:
    $153.55万
  • 财政年份:
    2023
  • 负责人:
    Deborah E. Barnes
  • 依托单位:
BRAIN HEALTH TOGETHER: A LIVE-STREAMING GROUP-BASED DIGITAL PROGRAM
  • 批准号:
    10747235
  • 项目类别:
  • 资助金额:
    $5.0万
  • 财政年份:
    2021
  • 负责人:
    Deborah E. Barnes
  • 依托单位:
BRAIN HEALTH TOGETHER: A LIVE-STREAMING GROUP-BASED DIGITAL PROGRAM
  • 批准号:
    10493302
  • 项目类别:
  • 资助金额:
    $97.91万
  • 财政年份:
    2021
  • 负责人:
    Deborah E. Barnes
  • 依托单位:
BRAIN HEALTH TOGETHER: A LIVE-STREAMING GROUP-BASED DIGITAL PROGRAM
  • 批准号:
    10324919
  • 项目类别:
  • 资助金额:
    $150.5万
  • 财政年份:
    2021
  • 负责人:
    Deborah E. Barnes
  • 依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2010
  • 负责人:
    梁胜
  • 依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2010
  • 负责人:
    郭亚芬
  • 依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究